Navigation Links
PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
Date:9/9/2011

OXFORD, England, September 9, 2011 /PRNewswire/ --

PharmaVentures Limited, experts in deals and alliances, are pleased to announce that they have been engaged by leading drug discovery company, Astex Pharmaceuticals to seek a buyer for an established full service CMC (chemistry, manufacturing & controls) & Formulation Facility in Pleasanton, California. The engagement will utilise PharmaVentures' asset divestment expertise in the life sciences sector.

Dr Fintan Walton, CEO, PharmaVentures commented, "We are delighted to have been chosen by Astex to assist in divesting this state-of-the-art facility, maximising return for the stakeholders.  With 20 years' experience of transactions, PharmaVentures can provide Astex with access to key decision makers in relevant companies with a view to safeguarding the future of the site."

The facility is part of the recent integration of Astex Therapeutics Limited and SuperGen Inc. and provides an opportunity to build out a fully integrated CMC capability in a prime but low cost West Coast US location.  The site's team has significant experience in preclinical as well as Phase I, II and III drug product development as evidenced by over 30 patents and the successful oversight of a number of global regulatory filings.

PharmaVentures is a leading life sciences transaction advisory firm with strong capabilities in finding and evaluating opportunities and negotiating deals.  The transactions team has an established track record in generating outstanding value for PharmaVentures' clients and has assisted in over 100 transactions in the past 20 years.  

For enquiries regarding this opportunity or how we can help your company to achieve its business goals, please contact:

Dr Jansen Jacobs
Senior Advisor
PharmaVentures Ltd
jansen.jacobs@pharmaventures.com
+44-7951-205420


'/>"/>
SOURCE Pharma Ventures Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
2. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
3. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
4. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
5. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
6. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
7. FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech
8. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
9. PTC Therapeutics and Genzyme Announce Restructuring of Collaboration
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Randomized Study Comparing Cell Therapeutics OPAXIO (Paclitaxel Poliglumex) and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015   GenoSpace , a leading provider ... analysis of genomic and other biomedical data, today ... the company as Vice President of Sales and ... "GenoSpace partners with its customers ... and explore complex sets of genomic, phenotypic and ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's ... designed for continuous operation up to 1500 bar. The sanitary design gauge of ... preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal solution for ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... ... Countries, - Competitors Precluded from Immediate Commercialization of Competitive ... Products, ... TSX.V.NTB) announces that the,European Patent Office (EPO) granted on May 31st 2007 Neptune,s composition,of ...
... Expected to Yield Multiple New Drug Products for Aida,s ... ... Calif., March 27 Aida,Pharmaceuticals, Inc (OTC Bulletin Board: AIDA) today ... Jiangsu,Institute of Microbiology Co., Ltd. ("JSIM") Aida,s subsidiary, Hanzhou,Aida Pharmaceuticals Co., ...
... through conversion of agricultural ... products into advanced materials, COLUMBUS, Ohio, ... representing a wide range of expertise in the,fields of chemicals, ... Chemicals, Polymers, and Advanced Materials Task Force. The,creation of the ...
Cached Biology Technology:Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications 2Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications 3Aida Acquires High-Level Research Institute in China 2Ohio Task Force Begins Mission of Creating a New 21st Century Industry 2Ohio Task Force Begins Mission of Creating a New 21st Century Industry 3
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... 7, 2008 The Global Innovation Imperatives (Gii) ... for their first session at the American Chemical ... Gii, a joint collaboration between the ACS Committee ... Industry, seeks to combat worldwide health, environmental and ...
... is a poorly understood condition that incapacitates and affects the ... In the US, it affects approximately six million women and ... It is a chronic painful disease which occurs when ... the area of the ovaries and fallopian tubes, but can ...
... the fact that millions of Americans are believed to have ... to treat many of these people. That is due in ... are varied and complex, ranging from chronic allergies, viral infection, ... percent of Americans have lost their sense of smell and ...
Cached Biology News:At ACS' national meeting, global initiative set to tackle water issues 2New study finds uncontrollable stress worsens symptoms of endometriosis 2New study finds uncontrollable stress worsens symptoms of endometriosis 3For some who have lost their sense of smell, a once popular asthma drug could help 2For some who have lost their sense of smell, a once popular asthma drug could help 3
Hamster serum...
... Dye Pack, 12 x Cy5. The ... for microarray labeling.Higher reactivity Cy3 and ... per vial, at > 75% reactive ... and packed in foil packs for ...
Collected from sexually mature, mixed sex, mixed breed dogs. Serum from specific breeds available by request....
... Power Supply, 1. 300 V, 400 ... constant current modes.Single-unit increments in settings ... for submarine, mini vertical, and standard ... semidry and mini tank blotting applications. ...
Biology Products: